Skip to main content

Gastrointestinal Cancer Metastatic clinical trials at University of California Health

2 in progress, 0 open to eligible people

Showing trials for
  • Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

    Sorry, in progress, not accepting new patients

    This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapazamine will be given by intra-arterial injection before embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat treatment is necessary only if disease progression. Dose escalation cohort has been completed. Expansion cohort is open for metastatic liver dominant neuroendocrine tumor.

    at UC Irvine UCSF

  • Electronic Patient Reported Outcomes in Patients With Gastrointestinal Cancers

    Sorry, not yet accepting patients

    This is a randomized trial of patients with gastrointestinal (GI) cancers treated at University of California, San Francisco (UCSF) who are starting a new line of systemic therapy to evaluate the feasibility of electronic patient reported outcome (ePRO) platform.

    at UCSF

Our lead scientists for Gastrointestinal Cancer Metastatic research studies include .

Last updated: